Valneva (VALN) has released an update.
Valneva SE, a specialty vaccine company, has announced participation at several major investor conferences in the U.S. and Europe throughout June 2024 to discuss their leading Lyme Disease vaccine candidate VLA15, in partnership with Pfizer, as well as other vaccine developments. The company will also cover their commercial business strategies, including the launch of IXCHIQ®, the only approved chikungunya vaccine, and provide updates on their second-generation Zika virus vaccine candidate VLA1601, currently in Phase 1 clinical development.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
